胆管癌治疗药物培美替尼在哪买的到？

Pemetinib (Pemazyre), developed by the American company Incyte, is a potent and selective oral inhibitor targeting FGFR subtypes 1/2/3. In April 2020, it was approved by the US FDA for marketing, for the treatment of adult patients with previously treated FGFR2 fusion or rearrangement of unresectable locally advanced or metastatic cholangiocarcinoma.

According to data from a study, the intrahepatic cholangiocarcinoma-targeted drug pemetinib can achieve an objective response rate of 35.5% and a disease control rate of 82% in the treatment of patients with cholangiocarcinoma. The median duration of response was 9.1 months, with as many as 63% of patients having a response duration of ≥6 months and 18% of patients with a duration of ≥12 months. It is not difficult to see from these data that the targeted drug pemetinib has a very significant effect on disease control and prognosis improvement of intrahepatic cholangiocarcinoma. The advent of the targeted drug pemetinib is good news for many patients with intrahepatic cholangiocarcinoma. This drug has changed the current treatment status of intrahepatic cholangiocarcinoma and provided doctors and patients with a new diagnosis and treatment plan.

Where can I buy the bile duct cancer treatment drug pemetinib? At present, pemetinib is not yet available in the domestic market. If patients need the drug, they can only purchase the version of pemetinib that is available overseas. According to Medical Travel, the original drug Pemetinib is sold in the United States in three specifications: 4.5 mg*14 tablets/box, 9 mg*14 tablets/box and 13.5 mg*14 tablets/box. The price of 13.5 mg*14 tablets/box is approximately US$17,800. If a friend of the patient needs it, he or she can go abroad to buy it by himself, or contact a legal and formal overseas medical service institution in China, sign a guarantee contract, and have 100% genuine medicines delivered directly to you without leaving home. If you have any other related questions that you need to consult, you can contact the Medical Companion Travel Service.

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.

Recommended related articles: